Blood Cancer in the News: Paul Allen, Roman Reigns, Scott WilsonOver the last few weeks, blood cancer has been in the news due to the passing of celebrities Paul Allen and Scott Wilson, as well as surprise announcement by wrestler... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Next-Generation Sequencing Test for Minimal Residual Disease of ALL and Multiple MyelomaOn September 28, 2018, the U.S. Food and Drug Administration (FDA) approved the first next-generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves Copiktra for CLL/SLL and Follicular LymphomaOn September 24, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment for certain types of blood cancer: Copiktra (duvelisib). Manufactured by Verastem, Copiktra is approved to... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Lumoxiti for Hairy Cell LeukemiaOn September 13, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment option for adults with hairy cell leukemia (HCL) who have tried at least two prior... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Non-Chemotherapy Combination for Waldenstrom MacroglobulinemiaThe U.S. Food and Drug Administration (FDA) has approved the combination of Imbruvica® (ibrutinib) with Rituxan® (rituximab) for the treatment of Waldenstrom macroglobulinemia in adults. This is the first non-chemotherapy... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Keytruda for Refractory or Relapsed Primary Mediastinal Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has recently given accelerated approval for Keytruda (pembrolizumab) to treat adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Expands Venclexta Approval for Broader Treatment of CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta (venetoclax). Venclexta is now approved to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
Take the Clinical Trial Patient Experience Survey!Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short survey to understand how patients are involved in the clinical... By Editorial Team 1 min readBookmark for laterReactions 0 reactions Comments0 comments
Expanded Approval for Darzalex – Newly Diagnosed, Transplant-Ineligible Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has recently expanded the usage of Darzalex (daratumumab): it is now approved to be used in combination with Velcade (bortezomib), melphalan, and prednisone... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
CAR T-Cell Therapy Kymriah Now Approved for Adult Diffuse Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) recently expanded the approval of Kymriah™ (tisagenlecleucel) to include adults with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma... By Emily Downward3 min readBookmark for laterReactions 0 reactions Comments0 comments